Business
– In its 2014 guidance Teva provides a pessimistic scenario with generic Copaxone competition, and an optimistic one with Copaxone exclusivity. – CEO Eyal...
Hi, what are you looking for?
– In its 2014 guidance Teva provides a pessimistic scenario with generic Copaxone competition, and an optimistic one with Copaxone exclusivity. – CEO Eyal...
– Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), issued the following statement regarding an article published by The Marker : “The company is aware...
– “I’m proud of my previous job at Teva, which was built so impressively by Eli Hurvitz. Teva has wonderful and dedicated people who...
– The network security company’s main patents are about to expire. – Check Point’s founder, chairman and CEO Gil Shwed – / By Shmulik Shelach...
– The medical devices company plans to raise the money at a company valuation of $500 million by February. – – Sources inform ”Globes”...
– Acting CEO Eyal Desheh / Getty – Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) acting CEO Eyal Desheh today said that Copaxone continued to lead...
– We learned officially today that Jeremy Levin CEO is leaving Teva behind and has resigned.Jewish Business News reported yesterday on a purported row...
The Laquinimod-treated patients accumulated significantly less brain tissue damage caused by neurodegeneration, compared to placebo in MRI analyses.
– This approval provides the regulatory framework for the commercialization of Lonquex in all 28 EU countries. – Illustration Teva Pharmaceutical Industries Ltd...
– – Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) and Switzerland’s Lonza Group AG (SXW: LONN) announced today that, following a strategic review...